15 January 2020 - UCB Canada announced today that Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.

The approval marks the fifth indication for Cimzia, which is the only Fc-free, PEGylated anti-TNF option available for the treatment of the disease where significant unmet need currently exists.

Read UCB press release